tetano
Editor, Senior Moderator
Cardiovasc Res. 2020 Apr 15. pii: cvaa097. doi: 10.1093/cvr/cvaa097. [Epub ahead of print]
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Kreutz R[SUP]1[/SUP], Algharably EAE[SUP]1[/SUP], Azizi M[SUP]2[/SUP], Dobrowolski P[SUP]3[/SUP], Guzik T[SUP]4[/SUP], Januszewicz A[SUP]3[/SUP], Persu A[SUP]5[/SUP], Prejbisz A[SUP]3[/SUP], Riemer TG[SUP]1[/SUP], Wang JG[SUP]6[/SUP], Burnier M[SUP]7[/SUP].
Author information
Abstract
Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic.
Published on behalf of the European Society of Cardiology. All rights reserved. ? The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
KEYWORDS:
Angiotensin; COVID-19; Cardiovascular; Hypertension; Lung
PMID:32293003DOI:10.1093/cvr/cvaa097
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Kreutz R[SUP]1[/SUP], Algharably EAE[SUP]1[/SUP], Azizi M[SUP]2[/SUP], Dobrowolski P[SUP]3[/SUP], Guzik T[SUP]4[/SUP], Januszewicz A[SUP]3[/SUP], Persu A[SUP]5[/SUP], Prejbisz A[SUP]3[/SUP], Riemer TG[SUP]1[/SUP], Wang JG[SUP]6[/SUP], Burnier M[SUP]7[/SUP].
Author information
Abstract
Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic.
Published on behalf of the European Society of Cardiology. All rights reserved. ? The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
KEYWORDS:
Angiotensin; COVID-19; Cardiovascular; Hypertension; Lung
PMID:32293003DOI:10.1093/cvr/cvaa097